Aralez Pharmaceuticals Inc (ARZ) Given Buy Rating at Chardan Capital
Aralez Pharmaceuticals Inc (TSE:ARZ)‘s stock had its “buy” rating restated by Chardan Capital in a research report issued to clients and investors on Wednesday.
Separately, Bloom Burton upgraded shares of Aralez Pharmaceuticals from an “accumulate” rating to a “buy” rating in a report on Monday, April 10th.
Aralez Pharmaceuticals (TSE:ARZ) opened at 2.02 on Wednesday. The company’s market cap is $132.68 million. Aralez Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $8.75. The company has a 50-day moving average of $2.16 and a 200 day moving average of $4.68.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/05/20/aralez-pharmaceuticals-inc-arz-given-buy-rating-at-chardan-capital.html.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.